International Development: Diseases of Poverty

Baroness Kinnock of Holyhead Excerpts

Wednesday 24th July 2013 Lords Chamber

[Baroness Northover]

DfID has provided approximately £60 million for biomedical and scientific research into HIV/AIDS and £39 million for TB research over the past five years. Spending for the next five years is dependent on the results of the ongoing product development partnerships competition. If my noble friend looks online, she will find DfID’s research strategy priorities and commissioning practices, which were published earlier this year as part of the International Development Committee’s annual accounts inquiry. This information is also in the Library.

[Baroness Kinnock of Holyhead]

My Lords, while a malaria vaccine is the biggest need at this time, it receives virtually no research funding. Currently, 10 times more is spent on a cure for male baldness than on a cure for malaria. Does the Minister agree that the research conducted by pharmaceutical companies focuses, as Bill Gates has said, on what is most lucrative and not on what is most needed? Does she agree with him that it is unlikely that the global poor will ever be profitable enough to attract the interest of the pharmaceutical industry?

[Baroness Northover]

The noble Baroness gets to the nub of the problem. This is why special effort must go into supporting research in these areas because it is, of course, the poorest who suffer from these diseases and cannot pay the prices for the drugs. I think about 1% of any investment went into this area of neglected tropical diseases, which is of course why Gates took it up. At the moment, he funds 49% of the research being taken forward. That is a template for what we are doing and why we are supporting it.